Clinical Trial


A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities


Brief description

This randomized, double-blind, placebo-controlled, parallel group, multicenter study will evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with stable cardiovascular disease and glucose abnormalities. Patients will be randomized 1:1 to receive either aleglitazar 150 mcg orally daily or matching placebo.

Keywords

  •   Cardiovascular Disease, Diabetes Mellitus Type 2

Sponsored By

Hoffmann-La Roche

Unique Study ID

NCT01715818

Investigators and Research Sites Near You - Found( 3 )

No Investigator Listed

Regeneron Pharmaceuticals
50368, Wroclaw, Dolnoslaskie, Poland
Distance from Current Trial is 0 miles

No Investigator Listed

Bristol-Myers Squibb
51-620, Wroclaw, Poland
Distance from Current Trial is 0 miles

No Investigator Listed

Wroclaw Medical University
50-556, Wroclaw, Dolnośląskie, Poland
Distance from Current Trial is 0 miles
View All